Ann Cahill

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

John Nemunaitis, Casey Cunningham, Neil Senzer et al. · Cancer Gene Therapy · 2003 · 332 citations

E. Coli, Pilot Trial, Pathogen Detection +10

Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Francis J. Giles, Paula M. Fracasso, Hagop M. Kantarjian et al. · Leukemia Research · 2003 · 91 citations

Pharmacodynamic Study, Advanced Leukemia, Medicine +7

Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia

Francis G. Giles, David A. Rizzieri, Judith E. Karp et al. · Journal of Clinical Oncology · 2006 · 84 citations

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Gary J. Schiller, Susan O’Brien, Arnaud Pigneux et al. · Journal of Clinical Oncology · 2009 · 74 citations · Full text

Elderly Patients, Mixed-phenotype Acute Leukemia, Pharmacotherapy +20

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

Francis J. Giles, Norbert Vey, Daniel J. DeAngelo et al. · Blood · 2009 · 54 citations